ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos147.94 M153.46 M159.96 M168.9 M181.1 M663.42 MInvestigación y desarrollo20.01 M22.08 M23.22 M22.68 M21.79 M89.77 MBeneficio operativo42.77 M40.35 M40.83 M48.84 M59.23 M189.25 MTotal de ingresos no operativos1.56 M3.51 M4.48 M3.49 M4.4 M15.88 MGastos por intereses, netos de intereses capitalizados336 K322 K319 K338 K332 K1.31 MIngresos no operativos, una vez deducidos los gastos por intereses2.6 M2.74 M3.35 M3.68 M3.9 M13.67 MIngresos/gastos extraordinarios-1.38 M445 K812 K-535 K171 K893 KBeneficio antes de impuestos44.34 M43.86 M45.31 M52.33 M63.63 M205.13 MParticipación en los beneficios——————Impuestos10.66 M4.63 M40 K6.47 M16.29 M27.44 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas33.68 M39.22 M45.27 M45.85 M47.34 M177.69 MOperaciones suspendidas——————Beneficio neto33.68 M39.22 M45.27 M45.85 M47.34 M177.69 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas33.68 M39.22 M45.27 M45.85 M47.34 M177.69 MBeneficio básico por acción0.871.021.171.171.214.57Beneficio por acción diluido0.8811.151.171.24.52Número medio de acciones ordinarias38.63 M38.56 M38.83 M39.08 M38.92 M155.39 MAcciones diluidas39.27 M39.16 M39.25 M39.3 M39.29 M157 MEBITDA47.16 M45.37 M46.34 M51.33 M63.69 M206.72 MEBIT42.77 M40.35 M40.83 M48.84 M59.23 M189.25 MCosto de los ingresos104.8 M108.26 M115.44 M114.27 M123.26 M461.23 MOtros costes de producción2.71 M2.48 M775 K973 K1.54 M5.77 MAmortización y depreciación (flujo de caja)4.39 M5.01 M5.51 M2.49 M4.46 M17.47 M
Penumbra Inc
Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.
In January 2026, Boston Scientific announced it would acquire Penumbra in a $15 billion cash and stock deal. The deal was expected to close by yearend.